In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now.
The head biotech analyst at Goldman Sachs, Salveen Richter, made an appearance on CNBC’s “Squawk Box” on July 25 to discuss a variety of topics, including the status of the biotech industry and what to anticipate from the earnings season.
She said that the biotech and healthcare industries have experienced several years of negative earnings revision cycles, and she wants to see these businesses now hitting the figures.
They have begun to show some steadiness, Richter continued, and Q2 is usually a stronger quarter. As a result, some biotech businesses in the sector could produce impressive financial outcomes.
According to the expert, launches and pipelines beyond statistics are two more elements to take into account in the sector.
She mentioned that she will continue to keep an eye on the several medicine launches that have occurred this year. Speaking of pipelines that go beyond statistics, Richter said that pain and Alzheimer’s disease have begun to receive attention this season.
With this in mind, let’s now take a look at the top AI-Powered biotech stocks to buy now.
Our Methodology
For our methodology, we initially identified AI-powered companies through manual research and shortlisted 20 leading firms. From this list, we selected the 10 companies with the highest number of hedge fund holders as of Q2 2025, according to Insider Monkey’s database, and then ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Here is our list of the top 10 AI-powered biotech stocks to buy now.
10. Absci Corporation (NASDAQ:ABSI)
Number Of Hedge Fund Holders: 12
Absci Corporation (NASDAQ:ABSI), founded in 2018 and headquartered in Seattle, is pioneering the integration of deep learning with high-throughput lab automation to design and optimize biologics at scale. Its Integrated Drug Creation (IDC) platform combines proprietary algorithms with protein engineering, enabling rapid development of antibody and enzyme candidates for both pharma partners and its own pipeline. The stock is among the best biotech stocks.
Absci Corporation (NASDAQ:ABSI) recently expanded its partnership with Almirall, a leading dermatology-focused pharmaceutical firm, by launching a second program targeting chronic skin diseases. This builds on the successful delivery of a functional AI-designed antibody, further validating the firm’s technology. To strengthen its dermatology pipeline, Absci also appointed experts Dr. Rodney Sinclair and Dr. David Goldberg to advise on ABS-201, an AI-designed therapy for hair loss disorders such as androgenetic alopecia, which is expected to enter clinical evaluation in early 2026.
On the technology front, the business announced collaborations with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery capabilities. The AMD partnership includes a strategic investment, giving the company access to advanced chip technology and cloud resources to scale model training and data processing.
Financially, Absci Corporation (NASDAQ:ABSI) boosted its balance sheet with $64 million in equity financing during July and August 2025, extending its operational runway through mid-2028. The funding will support the advancement of key pipeline programs, including ABS-101 and ABS-201, while accelerating partnered projects and strengthening the corporation’s AI infrastructure for next-generation drug discovery.
9. AbCellera Biologics Inc. (NASDAQ:ABCL)
Number Of Hedge Fund Holders: 17
AbCellera Biologics Inc. (NASDAQ:ABCL) is entering a new phase in 2025, shifting from discovery to clinical execution with multiple first-in-human trials now underway. In August, the company began Phase 1 studies for two AI-designed antibodies: ABCL575, targeting moderate-to-severe atopic dermatitis, and ABCL635, a first-in-class treatment for menopausal hot flashes. Both candidates leverage novel mechanisms, with ABCL575 showing strong safety and extended dosing potential, while ABCL635 offers a non-hormonal alternative for symptoms that remain underserved by current therapies.
Strengthening its leadership team, AbCellera Biologics Inc. (NASDAQ:ABCL) appointed Dr. Sarah Noonberg as Chief Medical Officer in September. Her expertise in clinical development is expected to accelerate regulatory progress and support the company’s expansion into new therapeutic areas, particularly immunological diseases.
The corporation’s momentum is reflected in its growing pipeline, which now includes 16 molecules in clinical development, alongside 97 initiated partner programs. This underscores robust demand for the business’s AI-powered antibody discovery platform, which combines advanced epitope mapping, microfluidics, and data-driven optimization to shorten the path from target identification to clinical trials.
Looking ahead, AbCellera Biologics Inc. (NASDAQ:ABCL) plans to launch additional clinical trials by the end of 2025, expand its integrated manufacturing capabilities, and continue scaling its AI platform.
8. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Number Of Hedge Fund Holders: 21
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech, is pioneering the use of artificial intelligence and machine learning to accelerate drug discovery, with a focus on rare diseases and oncology. Its proprietary Recursion OS combines high-throughput biology and multimodal datasets to streamline therapeutic development.
In September 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock surged nearly 7% following progress across key programs and regulatory milestones. A pivotal step was the $12.5 million milestone payment to Rallybio, tied to the advancement of REV102, an investigational ENPP1 inhibitor for the rare disease hypophosphatasia. This achievement underscores the company’s strategy of advancing innovative assets through collaborative development.
On the technology front, Recursion deepened its AI integration through the launch of Boltz-2, a model built with MIT on the BioHive-2 platform to enhance predictions for small molecule–protein interactions. A recent merger with Exscientia further expanded its capabilities, combining expertise in small molecule design with the business’s AI-driven infrastructure. These moves position the company as one of the best biotech stocks leveraging AI to accelerate discovery.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s pipeline now centers on six lead candidates, four oncology programs, and two rare disease therapies. Key assets, including REC-aK7 for cancer and REC-4881 for familial adenomatous polyposis, continue advancing in clinical trials, with updates expected at major industry conferences this month.
The corporation’s September highlights also include FDA progress on rare disease assets, expanded collaborations with MIT, Tempus, and HealthVerity, and growing investor engagement, reflected in presentations such as Needham’s healthcare session in New York.
7. Relay Therapeutics, Inc. (NASDAQ:RLAY)
Number Of Hedge Fund Holders: 27
Relay Therapeutics, Inc. (NASDAQ:RLAY) is advancing its position in AI-powered oncology with a focus on targeting protein dynamics through computational modeling, structural biology, and molecular simulations. Its proprietary platform is designed to create small-molecule drugs that address complex cancer pathways once considered untreatable.
Relay Therapeutics, Inc. (NASDAQ:RLAY) ’s lead candidate, RLY-2608, a PIK3CA inhibitor, is in late-stage trials for breast cancer and has emerged as a major driver of momentum this month. Recent data show strong efficacy and a clean safety profile, drawing significant analyst attention and positioning the therapy as a front-runner in precision oncology. Beyond breast cancer, RLY-2608 is also being evaluated for vascular malformations, opening potential pathways into rare pediatric indications. This progress has sparked optimism, with analysts assigning a buy rating and projecting a price target nearly four times current levels.
Relay Therapeutics, Inc. (NASDAQ:RLAY) is further strengthening its pipeline through collaborations with Pfizer and Elevar Therapeutics, partnerships that are expected to accelerate commercialization and broaden clinical adoption. Alongside RLY-2608, the corporation is expanding its portfolio of small-molecule inhibitors to tackle hard-to-treat cancers, supported by its integration of high-performance computing, experimental validation, and strategic alliances.
6. Moderna, Inc. (NASDAQ:MRNA)
Number Of Hedge Fund Holders: 39
Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, specializes in mRNA therapeutics and vaccines, including its flagship COVID-19 vaccine. Beyond the pandemic, the company is expanding its pipeline with vaccines for influenza, RSV, CMV, Zika, and combination vaccines targeting multiple respiratory pathogens, alongside mRNA therapeutics for oncology, rare diseases, and cardiovascular conditions. MRNA operates globally with manufacturing in the U.S. and Europe, leveraging strategic alliances and technology transfers to scale its operations.
In September 2025, Moderna, Inc. (NASDAQ:MRNA) faced market headwinds as its stock fell nearly 7%, triggered by reports linking COVID-19 vaccines to about 25 child deaths, a claim lacking scientific consensus but fueling investor concerns and regulatory scrutiny. Policy shifts, including Florida’s removal of vaccine mandates, further cloud near-term demand forecasts.
Despite these challenges, the firm emphasizes transparency and scientific rigor, citing extensive real-world data with over a billion doses administered worldwide. This ongoing focus on safety underpins public trust and regulatory engagement.
Innovation remains central to Moderna, Inc. (NASDAQ:MRNA)’s strategy, with the company broadening mRNA applications beyond COVID-19. AI and machine learning are increasingly integrated into MRNA’s R&D pipeline to accelerate mRNA design, optimize vaccine formulations, and predict immune responses. This combination of scientific rigor and technological edge reinforces MRNA’s standing among the best biotech stocks adapting to future healthcare needs.
5. Structure Therapeutics Inc. (NASDAQ:GPCR)
Number Of Hedge Fund Holders: 44
Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases such as obesity and diabetes. Leveraging AI-powered drug discovery, the company designs and optimizes candidates with greater speed and precision, positioning itself as a leading AI-driven biotech innovator.
Structure Therapeutics Inc. (NASDAQ:GPCR)’s lead obesity candidate, aleniglipron (GSBR-1290), is progressing through two Phase 2b studies, ACCESS and ACCESS II, testing doses up to 240 mg to optimize efficacy and competitive positioning. Topline results are expected by year-end 2025, representing a key catalyst for validating its AI-enabled approach in clinical settings. In addition, the company plans to initiate Phase 1 trials for ACCG-2671, an oral amylin receptor agonist, expanding its metabolic disease portfolio with therapies potentially complementary to GLP-1 drugs.
Financially, Structure Therapeutics Inc. (NASDAQ:GPCR) reported a net loss of $61.7 million in Q2 2025, reflecting heavy investment in research and development, with a strong cash position of approximately $786.5 million supporting operations through 2027. Recent presentations at major healthcare investor conferences have highlighted clinical progress, commercialization potential, and the company’s AI-driven innovation strategy.
The firm’s AI-powered platform distinguishes it from traditional biotech firms by focusing on orally available therapies, which could improve patient accessibility and compliance. As the company approaches pivotal Phase 2b readouts for aleniglipron and prepares for ACCG-2671 trials, it demonstrates the potential of AI integration to accelerate drug discovery and strengthen its pipeline in a rapidly growing obesity and metabolic disorder market.
4. Gilead Sciences, Inc. (NASDAQ:GILD)
Number Of Hedge Fund Holders: 71
Gilead Sciences, Inc. (NASDAQ:GILD), headquartered in Foster City, California, continues to lead in antiviral and oncology therapies while advancing next-generation biologics through AI integration. Under CEO Daniel O’Day, the company is focusing on precision medicine and translational science to accelerate development and global patient access.
In September 2025, Gilead Sciences, Inc. (NASDAQ:GILD) broke ground on a new 180,000-square-foot Pharmaceutical Development and Manufacturing (PDM) Technical Development Center at its Foster City campus. The AI-enabled facility features autonomous robotics, real-time digital monitoring, and advanced infrastructure designed to streamline biologics production and accelerate technology transfer. This center is part of the firm’s $32 billion U.S. investment plan through 2030, aimed at strengthening domestic manufacturing capacity, supporting high-quality jobs, and embedding artificial intelligence into operational workflows.
The facility will enhance data-driven insights and process automation for therapies, including CAR-T treatments and next-generation antivirals, reflecting a strategic trend toward AI-powered efficiency and innovation. Gilead Sciences, Inc. (NASDAQ:GILD), often cited among the best biotech stocks, is uniting discovery, development, and manufacturing under digital-first platforms to reduce time-to-market for new therapies and bolster its competitive edge.
Beyond infrastructure, Gilead Sciences, Inc. (NASDAQ:GILD) is expanding its global health impact. A partnership with PEPFAR will deliver twice-yearly administration of lenacapavir for HIV prevention, targeting up to two million people in low- and lower-middle-income countries by the end of 2025. Regulatory submissions for lenacapavir for PrEP are planned in 18 key countries, reinforcing the corporation’s commitment to broadening access to life-saving treatments.
3. Pfizer Inc. (NYSE:PFE)
Number of Hedge Fund Holders: 83
Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to expand its mRNA vaccine and specialty medicine portfolio while maintaining focus on oncology, immunology, and infectious diseases. The company, widely recognized for its COVID-19 vaccine collaboration with BioNTech, recently announced significant progress with its LP.8.1-adapted COMIRNATY 2025-2026 formula.
In early September 2025, Pfizer Inc. (NYSE:PFE) reported positive Phase 3 topline data showing a fourfold increase in neutralizing antibodies in adults 65+ and high-risk adults 18–64. This adaptive vaccine targets emerging SARS-CoV-2 sublineages, supporting FDA approval and reinforcing PFE’s strategic direction to maintain vaccine efficacy in a changing pandemic landscape. The success highlights the broader potential of Pfizer’s mRNA platform, including applications in cancer immunotherapy.
Beyond vaccines, Pfizer Inc. (NYSE:PFE) is advancing oncology and specialty medicines. Combination therapy PADCEV plus KEYTRUDA has shown improved survival in bladder cancer, while HYMPAVZI continues to progress in hemophilia treatment. These developments illustrate the company’s commitment to high-need therapeutic areas.
Despite regulatory challenges, patent litigation over Paxlovid, and shifts in vaccine demand, the business continues to invest in R&D and strategic partnerships. The company’s focus on adaptive mRNA technology, AI-driven development, and precision medicine underscores its leadership among biotech innovators.
2. AbbVie Inc. (NYSE:ABBV)
Number Of Hedge Fund Holders: 89
AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader known for therapies across immunology, oncology, and neuroscience, recently secured a major development for its immunology portfolio. On September 11, 2025, the company announced a settlement with all generic manufacturers challenging Rinvoq (upadacitinib), extending its U.S. patent protection and exclusivity until 2037. This extension delays generic competition by about four years and is expected to help sustain Rinvoq’s blockbuster sales, which reached nearly $6 billion in 2024, supporting the firm’s transition as Humira revenues decline.
Rinvoq, approved for rheumatoid arthritis and multiple autoimmune disorders, is also undergoing clinical trials for additional indications such as alopecia areata, vitiligo, hidradenitis suppurativa, and systemic lupus erythematosus. This broad pipeline reflects AbbVie Inc. (NYSE:ABBV)’s strategic focus on expanding its immunology franchise and delivering next-generation therapies to underserved patient populations.
The corporation leverages AI and data analytics to support its drug development and pipeline management. AI-driven insights help optimize patient selection, accelerate clinical trials, and enhance treatment outcomes, although specific projects were not highlighted in recent news. Complementing this innovation, the company announced a $195 million expansion of its active pharmaceutical ingredient manufacturing facilities in mid-2025, strengthening its biotechnology and production capabilities.
With patent protection secured and a robust pipeline enhanced by AI-powered insights, AbbVie Inc. (NYSE:ABBV) positions itself for continued growth in immunology while maintaining momentum across its broader therapeutic portfolio.
1. Boston Scientific Corporation (NYSE:BSX)
Number Of Hedge Fund Holders: 100
Boston Scientific Corporation (NYSE:BSX) is emerging as a top AI-powered biotech stock by embedding artificial intelligence into its medical device portfolio, particularly in cardiology. Its AI strategy focuses on integrating advanced algorithms directly into revenue-generating devices like the WATCHMAN and FARAPULSE pulsed field ablation system, enhancing clinical outcomes and creating a “sticky” ecosystem for healthcare providers.
Recent developments highlight the FDA’s expanded approval of FARAPULSE for treating certain types of atrial fibrillation, a condition affecting nearly 60 million people globally. Boston Scientific Corporation (NYSE:BSX) also partners with AI platforms such as Anumana, which leverages data from millions of patients to improve diagnostics and treatment outcomes in electrophysiology and left atrial appendage closure (LAAC) procedures.
The firm combines internal R&D with strategic acquisitions and early-stage investments through its venture arm, enabling rapid commercialization of AI-enhanced technologies at scale. This approach supports expansion beyond cardiology into other areas such as endoscopy and urology, demonstrating the scalability of its AI initiatives across multiple medical divisions.
Boston Scientific Corporation (NYSE:BSX) recently reported strong organic sales growth of 17% year-over-year, including 28% growth in its WATCHMAN device. Key upcoming milestones include the commercialization of the Cortex OptiMap system combined with FARAPULSE and further AI-driven product launches and partnerships that reinforce Boston Scientific’s leadership in AI-enabled medical technology.
While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
